Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695280 | 0.91 | JAK2 (0.32) | — | |
| SCHEMBL26676175 | 0.91 | JAK2 (0.32) | — | |
| SCHEMBL26847812 | 0.85 | PDE3B (0.36) | PDE3BPDE3A | |
| SCHEMBL26847837 | 0.83 | PDE3B (0.34) | PDE3BPDE3ABCHEACHEDYRK1A | |
| SCHEMBL26847835 | 0.82 | PDE3B (0.34) | PDE3BPDE3AABL1 | |
| SCHEMBL26847855 | 0.82 | PDE3B (0.34) | PDE3BPDE3AABL1 | |
| SCHEMBL26847814 | 0.82 | PDE3B (0.34) | PDE3BPDE3AABL1 | |
| SCHEMBL26847839 | 0.81 | PDE3B (0.33) | PDE3BPDE3AABL1 | |
| SCHEMBL26847820 | 0.80 | PDE3B (0.38) | PDE3BPDE3ABCHEACHEDYRK1A | |
| SCHEMBL26847815 | 0.78 | PDE3B (0.36) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | PDE3B 517/4885PDE3A 513/4885BCHE 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.